Syntaxin
Engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases.
HQ location
Boulogne-Billancourt, France
Website
Launch date
Enterprise value
$206m
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
$206m Valuation: $206m | Acquisition | ||
| Total Funding | 000k | ||
Lundbeckfonden Ventures(exited)
Seventure Partners(exited)
SR One(exited)
Johnson & Johnson(exited)
Abingworth(exited)
Quest for Growth(exited)
EQT Life Sciences(exited)
| EUR | 2015 | 2016 | 2017 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| % growth | - | 38 % | (66 %) |
| EBITDA | 0000 | 0000 | 0000 |
| % EBITDA margin | 10 % | (4 %) | - |
| Profit | 0000 | 0000 | 0000 |
| % profit margin | 8 % | (4 %) | - |
| EV | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads